The Filing Desk

Arcutis Biotherapeutics vs Pharming Group

Arcutis Biotherapeutics ARQT · Pharming Group PHAR · Pharmaceuticals

Arcutis Biotherapeutics reported revenue of $376 million in fiscal 2025, about the same as Pharming Group's $376 million in fiscal 2025. Arcutis Biotherapeutics' revenue grew 91.3% in its latest year, and Pharming Group's grew 26.6%. Arcutis Biotherapeutics had an operating margin of -3.2%, against 6.9% at Pharming Group. Free cash flow was −$6 million at Arcutis Biotherapeutics and $54 million at Pharming Group.

Side by side

Arcutis BiotherapeuticsPharming Group
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$376M$376M
Revenue growth91.3%26.6%
Revenue growth a year, last 5 years—12.1%
Gross margin90.2%87.9%
Operating margin−3.2%6.9%
Net margin−4.3%0.8%
Free cash flow−$6M$54M
Free cash flow margin−1.7%14.3%
Return on capital−16.9%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count5.2%−4.9%
Last close$27.17$12.17
P/E at the last close129.4×—
Insider trades, last 12 monthssold $12.3 million—
Piotroski F-score4 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arcutis BiotherapeuticsPharming Group
Operating margin
Percent of revenue
Arcutis BiotherapeuticsPharming Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arcutis BiotherapeuticsPharming Group

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arcutis Biotherapeutics and Pharming Group pages.